Market Overview

UPDATE: Jefferies Raises PT on Questcor Pharmaceuticals on Strong Q4, Robust 2013 Outlook

Related QCOR
Morgan Stanley on Mallinckrodt: Controversy Around Acthar Unsettling
Eli Lilly/ Boehringer Drug Under FDA Review - Analyst Blog

In a report published Wednesday, Jefferies reiterated its Buy rating on Questcor Pharmaceuticals (NASDAQ: QCOR), and raised its price target from $30.00 to $38.00.

Jefferies noted, “QCOR beat on the topline and EPS on strong Acthar sales despite seasonal MS softness. While mgmt. expects Q1 headwinds including continued MS softness, inventory draw-down and administrative/distribution changes, it reiterated overall Acthar growth with favorable reimbursement outlook.”

Questcor Pharmaceuticals closed on Tuesday at $32.66.

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (QCOR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free